Abstract
Metastases of 47 known prostatic carcinomas were subjected to the unlabelled immunoperoxidase-procedure to localise prostaticacid-phosphatase (PAP) and prostatic-specific antigen (PSA). In bone-marrow, lymph-node, lung and liver metastases PAP was found in 64% and PSA in 78%. There was no significant difference between the intensity of staining in primary and metastatic neoplasm. In poorly differentiated metastases of prostatic adenocarcinomas less intense staining for PAP and PSA was found. The data suggest that the demonstration of PAP and PSA is a practical and sensitive test for the prostatic origin of a clinically and histologically unclassifiable metastasis.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
